Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases

Journal of Infection

Volumn 79, Issue 1, 2019, Pages 15-23

  Chiacchio, Teresa ^a   Petruccioli, Elisa ^a   Vanini, Valentina ^a   Cuzzi, Gilda ^a   Massafra, Umberto ^b   Baldi, Gianpiero ^c   Navarra, Assunta ^a   Scrivo, Rossana ^d   Mastroianni, Claudio ^e   Sauzullo, Ilaria ^e   Esposito, Carmela ^f   Palmieri, Fabrizio ^a   Cantini, Fabrizio ^f   Goletti, Delia ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c Civitavecchia   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Hospital of Prato   (Italy)

Author keywords

Anti TNF ; Biological therapy; IGRA; IMID; LTBI; QuantiFERON TB Plus; Tuberculosis

Indexed keywords

GAMMA INTERFERON;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SCREENING; IMMUNOLOGY; INFLAMMATION; INTERFERON GAMMA RELEASE ASSAY; MASS SCREENING; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES;

ADULT; AGED; FEMALE; HUMANS; INFLAMMATION; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES;

EID: 85064516918     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2019.04.010     Document Type: Article

References (37)

1. WHO. Global tuberculosis report 2018. www.who.int/tb/publications/global_report/en/. 2018.
2. Houben, R.M., Dodd, P.J., The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med, 13(10), 2016 25, e1002152.
3. Goletti, D., Petrone, L., Ippolito, G., Niccoli, L., Nannini, C., Cantini, F., Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther 16:6 (2018), 501–512.
4. Cantini, F., Nannini, C., Niccoli, L., Petrone, L., Ippolito, G., Goletti, D., risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted Biologics. Mediators Inflamm, 2017, 2017, 8909834.
5. Cantini, F., Niccoli, L., Goletti, D., Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-alpha) targeted biologics and recently licensed TNF-alpha inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 91 (2014), 56–64.
6. Baddley, J.W., Cantini, F., Goletti, D., Gomez-Reino, J.J., Mylonakis, E., San-Juan, R., et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents). Clin Microbiol Infect 24:Suppl 2 (2018), S10–S20.
7. Cantini, F., Nannini, C., Niccoli, L., Iannone, F., Delogu, G., Garlaschi, G., et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev 14:6 (2015), 503–509.
8. Goletti, D., Carrara, S., Vincenti, D., Saltini, C., Rizzi, E.B., Schinina, V., et al. Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. Clin Microbiol Infect 12:6 (2006), 544–550.
9. Goletti, D., Carrara, S., Butera, O., Amicosante, M., Ernst, M., Sauzullo, I., et al. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS One, 3(10), 2008, e3417.
10. Goletti, D., Lee, M.R., Wang, J.Y., Walter, N., Ottenhoff, T.H.M., Update on tuberculosis biomarkers: from correlates of risk, to correlates of active disease and of cure from disease. Respirology 23:5 (2018), 455–466.
11. Abubakar, I., Drobniewski, F., Southern, J., Sitch, A.J., Jackson, C., Lipman, M., et al. Prognostic value of interferon-gamma release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infect Dis 18:10 (2018), 1077–1087.
12. Kik, S.V., Schumacher, S., Maria Cirillo, D., Churchyard, G., Boehme, C., Goletti, D., et al. An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. Eur Respir J, 52(4), 2018, 10.1183/13993003.00946-2018 pii: 1800946.
13. Riou, C., Tanko, R.F., Soares, A.P., Masson, L., Werner, L., Garrett, N.J., et al. Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype. J Immunol 195:5 (2015), 2273–2281.
14. Chiacchio, T., Petruccioli, E., Vanini, V., Cuzzi, G., La Manna, M.P., Orlando, V., et al. Impact of antiretroviral and tuberculosis therapies on CD4(+) and CD8(+) HIV/M. tuberculosis-specific T-cell in co-infected subjects. Immunol Lett 198 (2018), 33–43.
15. Chiacchio, T., Petruccioli, E., Vanini, V., Cuzzi, G., Pinnetti, C., Sampaolesi, A., et al. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. J Infect 69:6 (2014), 533–545.
16. Barcellini, L., Borroni, E., Brown, J., Brunetti, E., Campisi, D., Castellotti, P.F., et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur Respir J 48:5 (2016), 1411–1419.
17. Petruccioli, E., Chiacchio, T., Pepponi, I., Vanini, V., Urso, R., Cuzzi, G., et al. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. J Infect 73:6 (2016), 588–597.
18. Petruccioli, E., Vanini, V., Chiacchio, T., Cuzzi, G., Cirillo, D.M., Palmieri, F., et al. Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis (Edinb) 106 (2017), 38–43.
19. Day, C.L., Abrahams, D.A., Lerumo, L., Janse van Rensburg, E., Stone, L., O'rie, T., et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol 187:5 (2011), 2222–2232.
20. Sauzullo, I., Mengoni, F., Mascia, C., Pavone, P., Savelloni, G., Massetti, A.P., et al. Diagnostic performance in active TB of QFT-Plus assay and co-expression of CD25/CD134 in response to new antigens of Mycobacterium tuberculosis. Med Microbiol Immunol 208:2 (2019), 171–183.
21. Petrone, L., Vanini, V., Chiacchio, T., Petruccioli, E., Cuzzi, G., Schinina, V., et al. Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection. Tuberculosis (Edinb) 111 (2018), 147–153.
22. Goletti, D., Lindestam Arlehamn, C.S., Scriba, T.J., Anthony, R., Cirillo, D.M., Alonzi, T., et al. Can we predict tuberculosis cure? What tools are available?. Eur Respir J, 52(5), 2018, 10.1183/13993003.01089-2018 Print 2018 Nov.
23. Igari, H., Ishikawa, S., Nakazawa, T., Oya, Y., Futami, H., Tsuyuzaki, M., et al. Lymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent tuberculosis infection in rheumatoid arthritis. J Infect Chemother 24:2 (2018), 110–116.
24. Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., Gonzalez-Lorenzo, M., Bastiampillai, A.J., et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 15:sup1 (2016), 11–34.
25. Petruccioli, E., Chiacchio, T., Vanini, V., Cuzzi, G., Codecasa, L.R., Ferrarese, M., et al. Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection. Sci Rep, 8(1), 2018 15626-018-33825-w.
26. Sauzullo, I., Scrivo, R., Sessa, P., Mengoni, F., Vullo, V., Valesini, G., et al. Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases. Sci Rep, 8(1), 2018 7881-018-26097-x.
27. Pieterman, E.D., Liqui Lung, F.G., Verbon, A., Bax, H.I., Ang, C.W., Berkhout, J., et al. A multicentre verification study of the QuantiFERON((R))-TB Gold Plus assay. Tuberculosis (Edinb) 108 (2018), 136–142.
28. Nemes, E., Rozot, V., Geldenhuys, H., Bilek, N., Mabwe, S., Abrahams, D., et al. Optimization and interpretation of serial QuantiFERON testing to measure acquisition of mycobacterium tuberculosis infection. Am J Respir Crit Care Med 196:5 (2017), 638–648.
29. Uzorka, J.W., Kroft, L.J.M., Bakker, J.A., van Zwet, E.W., Huisman, E., Knetsch-Prins, C., et al. Proof of concept that most borderline Quantiferon results are true antigen-specific responses. Eur Respir J, 50(5), 2017, 10.1183/13993003.01630-2017 Print 2017 Nov.
30. Uzorka, J.W., Delfos, N.M., Witte, A.M.C., Scheper, H., van Soolingen, D., Arend, S.M., Tuberculosis after a borderline QuantiFERON result during screening before infliximab. Eur Respir J, 52(2), 2018, 10.1183/13993003.00913-2018 Print 2018 Aug.
31. de Paus, R.A., van Meijgaarden, K.E., Prins, C., Kamphorst, M.H., Arend, S.M., Ottenhoff, T.H.M., et al. Immunological characterization of latent tuberculosis infection in a low endemic country. Tuberculosis (Edinb) 106 (2017), 62–72.
32. Leyten, E.M., Arend, S.M., Prins, C., Cobelens, F.G., Ottenhoff, T.H., van Dissel, J.T., Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol 14:7 (2007), 880–885.
33. Butera, O., Chiacchio, T., Carrara, S., Casetti, R., Vanini, V., Meraviglia, S., et al. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infect Dis, 9, 2009 182-2334-9-182.
34. Grzybowsky, S., Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Respir Dis 104:4 (1971), 605–608.
35. Goletti, D., Sanduzzi, A., Delogu, G., Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl 91 (2014), 24–31.
36. Goletti, D., Petrone, L., Ippolito, G., Niccoli, L., Nannini, C., Cantini, F., Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther 16:6 (2018), 501–512.
37. Wong, S.H., Gao, Q., Tsoi, K.K., Wu, W.K., Tam, L.S., Lee, N., et al. Effect of immunosuppressive therapy on interferon gamma release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax 71:1 (2016), 64–72.